Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency

Cell

Volumn 87, Issue 4, 1996, Pages 709-719

  Bugge, Thomas H ^a,b   Kombrinck, Keith W ^a   Flick, Matthew J ^a   Daugherty, Cynthia C ^a   Danton, Mary Jo S ^a   Degen, Jay L ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; PROCOLLAGENASE; SERINE PROTEINASE;

ANIMAL CELL; ARTICLE; EXTRACELLULAR MATRIX; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; LEUKOCYTE MIGRATION; MORTALITY; MOUSE; NONHUMAN; PHENOTYPE; PLASMINOGEN ACTIVATION; PLEIOTROPY; PRIORITY JOURNAL; RECTUM PROLAPSE; THROMBOSIS; WOUND HEALING;

ANIMALIA;

EID: 0030584083     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)81390-2     Document Type: Article

References (54)

1. Bode, V.C., and Dziadek, M.A. (1979). Plasminogen activator secretion during mouse embryogenesis. Dev. Biol. 73, 272-289.
2. Brunner, G., Gabrilove, J., Rifkin, D.B., and Wilson, E.L. (1991). Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. J. Cell. Biol. 6, 1275-1283.
3. Bugge, T.H., Flick, M.J., Daugherty, C.C., and Degen, J.L. (1995a). Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9, 794-807.
4. Bugge, T.H., Suh, T.T., Flick, M.J., Daugherty, C.C., Rømer, J., Solberg, H., Ellis, V., Danø, K., and Degen, J.L. (1995b). The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. Biol. Chem. 270, 16886-16894.
5. Bugge, T.H., Flick, M.J., Danton, M.J.S., Daugherty, C.C., Rømer, J., Danø, K., Carmeliet, P., Collen, D., and Degen, J.L. (1996). Urokinase plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA 93, 5899-5904.
6. Carmeliet, P., Schoonjans, L., Kieckens, L., Ream B., Degen, J.L., Bronson, R., DeVos, R., van den Oord, J.J., Collen, D., and Mulligan, R.C. (1994a). Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368, 419-424.
7. Carmeliet, P., Stassen, L., Schoonjans, L., Ream, B., van den Oord, J.J., De Mol, M., Mulligan, R.C., and Collen, D. (1994b). Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J. Clin. Invest. 92, 2756-2760.
8. Clark, R.A.F., and Henson, P.M., eds. (1988). The Molecular and Cellular Biology of Wound Repair (New York: Plenum).
9. Collen, D., and Lijnen, H.R. (1994). Fibrinolysis and the control of hemostasis. In The Molecular Basis of Blood Diseases, G.S. Stamatoyannopoulos, A.W. Nienhuis, P.W. Majerus, and H. Varmus, eds. (Philadelphia: W.B. Saunders Co.), pp. 725-752.
10. Crowley, C.W., Cohen, R.L., Lucas, B.K., Liu, G., Shuman, M.A., and Levinson, A.D. (1993). Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA 90, 5021-5025.
11. Danø, K., Andreasen, P.A., Grøndahl-Hansen, J., Kristensen, P., Nielsen, L.S., and Skriver, L. (1985). Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44, 139-266.
12. Danø, K., Behrendt, N., Brunner, N., Ellis, V., Ploug, M., and Pyke, C. (1994). The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 9, 189-203.
13. Dewerchin, M., Nuffelen, A.V., Wallays, G., Bouche, A., Moons, L., Carmeliet, P., Mulligan, R.C., and Collen, D. (1996). Generation and characterization of urokinase receptor-deficient mice. J. Clin. Invest. 97, 870-878.
14. Donaldson, D.J., and Mahan, J.T. (1988). Keratinocyte migration and the extracellular matrix. J. Invest. Dermatol. 90, 623-628.
15. Dumler, I., Petri, T., and Schleuning, W.D. (1993). Interaction of urokinase-type plasminogen activator with its cellular receptor uPAR induces phosphorylation on tyrosine on a 38 kDa protein. FEBS Lett. 3221, 37-40.
16. Dvorak, H.F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659.
17. Eitzman, D.T., McCoy, R.D., Zheng, X., Fay, W.P., Shen, T., Ginsburg, D., and Simon, R.H. (1996). Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor gene. J. Clin. Invest. 97, 232-237.
18. Grainger, D.J., Kemp, P.R., Liu, A.C., Lawn, R.M., and Medcalfe, J.C. (1994). Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 370, 460-462.
19. Gyetko, M., Chen, G.-H., McDonald, R.A., Goodman, R., Huffnagle, G.B., Wilkinson, C.C., Fuller, J.A., and Toews, G.B. (1996). Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. J. Clin. Invest. 97, 1818-1826.
20. Kook, Y.H., Adamski, J., Zelent, A., and Ossowski, L. (1994). The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 13, 3983-3991.
21. Leonardson, G., Peng, X.-R., Liu, K., Nordstrom, L., Carmeliet, P., Mulligan, R., Collen, D., and Ny, T. (1995). Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Proc. Natl. Acad. Sci. USA 92, 12446-12450.
22. Marotti, K.R., Belin, D., and Strickland, S. (1982). The production of distinct forms of plasminogen activator by mouse embryonic cells. Dev. Biol. 90, 154-159.
23. Mignatti, P., Robbins, E., and Rifkin, D.B. (1986). Tumor cell invasion through the human amniotic membrane. Requirement for a proteinase cascade. Cell 47, 487-498.
24. Moscatelli, D., and Rifkin, D.B. (1988). Membrane and matrix localization of proteases: a common theme in tumor cell invasion and angiogenesis. Biochim. Biophys. Acta. 948, 67-85.
25. Naldini, L., Tamagnone, L., Vigna, E., Sachs, M., Hartmann, G., Birchmeier, W., Daikuhara, Y., Tsubouchi, H., Blasi, F., and Comoglio, P.M. (1992). Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 11, 4825-4833.
26. Odekon, L.E., Blasi, F., and Rifkin, D.B. (1994). Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J. Cell. Physiol. 158, 398-407.
27. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H., and Folkman, J. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by Lewis lung carcinoma. Cell 79, 315-328.
28. Ossowski, L. (1988). Plasminogen activator dependent pathways in dissemination of human tumors in the chick embryo. Cell 52, 321-328.
29. Ossowski, L., and Reich, E. (1983). Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35, 611-619.
30. Ossowski, L., Clunie, G., Masucci, M.-T., and Blasi, F. (1991a). In vivo paracrine interactions between urokinase and its receptor: effect on tumor cell migration. J. Cell Biol. 115, 1107-1112.
31. Ossowski, L., Russo-Payne, H., and Wilson, E.L. (1991b). Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res. 51, 274-281.
32. Pepper, M.S., Vassalli, J.-D., Montesano, R., and Orci, L. (1987). Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J. Cell Biol. 105, 2435-2541.
33. Ploplis, V.A., Carmeliet, P., Vazirzadeh, S., Van Vlaenderen, I., Moons, L., Plow, E.F., and Collen, D. (1995). Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation Res. 92, 2585-2593.
34. Plow, E.F., and Edgington, T.S. (1986). Lymphocyte suppressive peptides from fibrinogen are derived predominantly from the Aα chain. J. Immunol. 137, 1910-1915.
35. Plump, A.S., Smith, J.D., Hayek, T., Aalto-Setala, K., Walsh, A., Verstuyft, J.G., Rubin, E.M., and Breslow, J.L. (1992). Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343-353.
36. Robson, S.C., Saunders, R., Purves, L.R., de Jager, C., Corrigal, A., and Kirch, R.E. (1993). Fibrin and fibrinogen degradation products with an intact D-domain C terminal gamma chain inhibit an early step in accessory cell-dependent lymphocyte mitogenesis. Blood 81, 3006-3014.
37. Robson, S.C., Shepard, E.G., and Kirch, R.E. (1994). Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL6 and plasminogen activator inhibitors from monocytes in vitro. Br. J. Haematol. 86, 322-326.
38. Rømer, J., Lund, L.R., Eriksen, J., Ralfkiaer, E., Zeheb, R., Gelehrter, T.D., Danø, K., and Kristensen, P. (1991). Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J. Invest. Dermatol. 97, 803-811.
39. Rømer, J., Lund, L.R., Eriksen, J., Pyke, C., Kristensen, P., and Danø, K. (1994). The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J. Invest. Dermatol. 102, 519-522.
40. Rømer, J., Bugge, T.H., Pyke, C., Lund, L.R., Flick, M.J., Degen, J.L., and Danø, K. (1996). Impaired wound healing in mice with a disrupted plasminogen gene. Nature Med. 2, 287-292.
41. Saksela, O., and Rifkin, D.B. (1988). Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell Biol. 4, 93-126.
42. Sappino, A.-P., Huarte, J., Belin, D., and Vassalli, J.-D. (1989). Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J. Cell Biol. 109, 2471-2479.
43. Sappino, A.-P., Huarte, J., Vassalli, J.-D., and Belin, D. (1991). Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J. Clin. Invest. 87, 962-970.
44. Skogen, W.F., Senoir, R.M., Griffin, G.L., and Wilner, G.D. (1988). Fibrinogen-derived peptide Bb1-42 is a multidomained neutrophil chemoattractant. Blood 71, 1475-1479.
45. Strickland, S., Reich, E, and Sherman M.I. (1976). Plasminogen activation in early embryogenesis: enzyme production by trophoblast and parietal endoderm. Cell 9, 231-240.
46. Strickland, D., Kounnas, M.Z., and Argraves, W.S. (1995). LDL receptor-related protein: a multiligand receptor for lipoprotein and proteinase catabolism. FASEB J. 9, 890-898.
47. Suh, T.T., Holmback, K., Jensen, N.J., Daughterly, C.C., Small, K., Simon, D.I., Potter, S.S., and Degen, J.L. (1995). Resolution of spontaneous bleeding but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 9, 2020-2033.
48. Thompson, W.D., Smith, E.B., Stirk, C.M., and Wang, J. (1993). Fibrin degradation products in growth stimulatory extracts of pathological lesions. Blood Coagul. Fibrinolysis 4, 113-115.
49. Trudel, M., De Paepe, M.E., Chretin, N., Saadane, C.N., Jacmain, J., Sorette, M., Hoong, T., and Beuzard, Y. (1994). Sickle cell disease of transgenic SAD mice. Blood 84, 3189-3197.
50. Valinsky, J.E., Reich, E., and Le Douarin N.M. (1981). Plasminogen activator in the bursa of Fabricius: correlations with morphogenetic remodeling and cell migrations. Cell 25, 471-476.
51. Vassalli, J.-D. (1994). The urokinase receptor. Fibrinolysis 8, 172-181.
52. Vassalli, J.-D., Sappino, A.-P., and Belin, D. (1991). The plasminogen activator/plasmin system. J. Clin. Invest. 88, 1067-1072.
53. Waltz, D.A., and Chapman, H.A. (1994). Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 269, 14746-14750.
54. Werb, Z., Mainardi, C., Vater, C.A., and Harris, E.D. (1977). Endogenous activation of latent collagenases by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N. Engl. J. Med. 296, 1017-1023.